Total Payments
$25,451
2024 Payments
$910.37
Companies
19
Transactions
69
Medicare Patients
1,711
Medicare Billing
$439,676
Payment Breakdown by Category
Other$17,990 (70.7%)
Food & Beverage$4,811 (18.9%)
Consulting$1,434 (5.6%)
Travel$695.11 (2.7%)
Education$520.56 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,840 | 9 | 70.1% |
| Food and Beverage | $4,811 | 48 | 18.9% |
| Consulting Fee | $1,434 | 1 | 5.6% |
| Travel and Lodging | $695.11 | 3 | 2.7% |
| Education | $520.56 | 7 | 2.0% |
| Honoraria | $150.00 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $20,621 | 21 | $0 (2023) |
| Veloxis Pharmaceuticals, Inc. | $1,039 | 9 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $791.52 | 6 | $0 (2024) |
| Astellas Pharma US Inc | $495.54 | 5 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $397.55 | 6 | $0 (2023) |
| Baxter Healthcare | $380.75 | 3 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $286.01 | 2 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $243.17 | 2 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $233.44 | 2 | $0 (2024) |
| Dynavax Technologies Corporation | $222.53 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $910.37 | 10 | Mallinckrodt Hospital Products Inc. ($136.02) |
| 2023 | $7,247 | 13 | GENZYME CORPORATION ($6,473) |
| 2022 | $8,135 | 14 | GENZYME CORPORATION ($7,349) |
| 2021 | $6,328 | 10 | GENZYME CORPORATION ($5,639) |
| 2020 | $1,002 | 4 | GENZYME CORPORATION ($782.00) |
| 2019 | $698.00 | 6 | Veloxis Pharmaceuticals, Inc. ($125.00) |
| 2018 | $409.72 | 4 | GENZYME CORPORATION ($284.72) |
| 2017 | $720.94 | 8 | Veloxis Pharmaceuticals, Inc. ($239.99) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: IMMUNOLOGY | ||||||
| 05/30/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $136.02 | General |
| Category: CRITICAL CARE | ||||||
| 05/14/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Infectious Diseases | ||||||
| 05/14/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/09/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $133.72 | General |
| Category: Rare Disease | ||||||
| 04/30/2024 | Baxter Healthcare | — | Food and Beverage | In-kind items and services | $131.16 | General |
| 03/25/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $115.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/01/2024 | Veloxis Pharmaceuticals, Inc. | — | Education | In-kind items and services | $91.50 | General |
| 12/15/2023 | SANOFI-AVENTIS U.S. LLC | THYMOGLOBULIN (Biological) | Food and Beverage | In-kind items and services | $12.23 | General |
| Category: Oncology | ||||||
| 10/14/2023 | GENZYME CORPORATION | FABRAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,310.00 | General |
| Category: Genetic Disease | ||||||
| 08/17/2023 | SANOFI-AVENTIS U.S. LLC | THYMOGLOBULIN (Biological) | Food and Beverage | In-kind items and services | $95.61 | General |
| Category: Oncology | ||||||
| 06/22/2023 | GENZYME CORPORATION | FABRAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,657.00 | General |
| Category: Genetic Disease | ||||||
| 06/22/2023 | GENZYME CORPORATION | FABRAZYME (Biological) | Travel and Lodging | Cash or cash equivalent | $36.68 | General |
| Category: Genetic Disease | ||||||
| 06/22/2023 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $35.63 | General |
| Category: Genetic Disease | ||||||
| 06/01/2023 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,434.00 | General |
| 04/04/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $175.16 | General |
| Category: Rare Disease | ||||||
| 03/29/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $121.83 | General |
| 03/16/2023 | Baxter Healthcare | — | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Surgical Care | ||||||
| 02/22/2023 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $149.99 | General |
| Category: CRITICAL CARE | ||||||
| 01/24/2023 | SANOFI-AVENTIS U.S. LLC | MOZOBIL (Drug) | Education | In-kind items and services | $75.99 | General |
| Category: Oncology | ||||||
| 01/20/2023 | SANOFI-AVENTIS U.S. LLC | THYMOGLOBULIN (Biological) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Oncology | ||||||
| 11/15/2022 | GENZYME CORPORATION | FABRAZYME (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,455.00 | General |
| Category: Genetic Disease | ||||||
| 11/15/2022 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $81.15 | General |
| Category: Genetic Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 377 | 775 | $219,885 | $89,543 |
| 2022 | 11 | 428 | 924 | $259,217 | $106,487 |
| 2021 | 11 | 439 | 897 | $262,928 | $111,608 |
| 2020 | 10 | 467 | 1,147 | $357,982 | $132,038 |
Total Patients
1,711
Total Services
3,743
Medicare Billing
$439,676
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 27 | 117 | $89,300 | $34,663 | 38.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 116 | 287 | $38,745 | $19,052 | 49.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 64 | 148 | $34,215 | $11,055 | 32.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 45 | 77 | $14,805 | $7,735 | 52.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 45 | 46 | $16,330 | $6,633 | 40.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 13 | 17 | $10,810 | $4,215 | 39.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 24 | $5,904 | $2,637 | 44.7% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 18 | 28 | $4,984 | $1,684 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 16 | $3,517 | $1,240 | 35.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 15 | $1,275 | $628.95 | 49.3% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 18 | 149 | $104,300 | $45,075 | 43.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 120 | 288 | $38,880 | $17,300 | 44.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 60 | 140 | $31,875 | $10,612 | 33.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 68 | 146 | $25,988 | $9,019 | 34.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 49 | 49 | $17,395 | $8,175 | 47.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 12 | 26 | $15,340 | $6,279 | 40.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 29 | $5,510 | $2,521 | 45.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 17 | $5,555 | $1,836 | 33.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 20 | $4,500 | $1,729 | 38.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $3,444 | $1,605 | 46.6% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 13 | 20 | $4,220 | $1,483 | 35.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 20 | 26 | $2,210 | $853.37 | 38.6% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 22 | 160 | $112,000 | $49,775 | 44.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 114 | 234 | $31,590 | $14,251 | 45.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 57 | 138 | $31,050 | $10,847 | 34.9% |
About Dr. Xiaoyi Ye, M.D
Dr. Xiaoyi Ye, M.D is a Nephrology healthcare provider based in Hartford, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1821279514.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Xiaoyi Ye, M.D has received a total of $25,451 in payments from pharmaceutical and medical device companies, with $910.37 received in 2024. These payments were reported across 69 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($17,840).
As a Medicare-enrolled provider, Ye has provided services to 1,711 Medicare beneficiaries, totaling 3,743 services with total Medicare billing of $439,676. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Internal Medicine
- Location Hartford, CT
- Active Since 11/21/2007
- Last Updated 07/11/2011
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1821279514
Products in Payments
- FABRAZYME (Biological) $16,800
- Envarsus (Drug) $582.53
- ULTOMIRIS (Biological) $422.37
- FABRAZYME (Drug) $319.84
- TERLIVAZ (Drug) $286.01
- THYMOGLOBULIN (Biological) $247.57
- LIVTENCITY (Drug) $243.17
- Envarsus XR (Drug) $239.99
- FARXIGA (Drug) $233.44
- Heplisav-B (Drug) $222.53
- Soliris (Drug) $150.00
- MOZOBIL (Drug) $149.98
- Cresemba (Drug) $125.00
- Envarsus XR (SP) (Drug) $125.00
- Vemlidy (Drug) $124.80
- Renal - Non Product Related (Biological) $124.59
- Veltassa (Drug) $121.95
- DALVANCE (Drug) $120.94
- ACTHAR (Biological) $112.09
- CRESEMBA (Drug) $109.55
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Hartford
Dr. Terrence Oder, M.d, M.D
Nephrology — Payments: $2,215
Nephrology $2,215
Dr. Scott Benson, Do, DO
Nephrology — Payments: $1,598
Nephrology $1,598
Diana Moise, Md, MD
Nephrology — Payments: $1,257
Nephrology $1,257
Dr. Joseph Singh, M.d, M.D
Nephrology — Payments: $1,122
Nephrology $1,122
Timothy Curley, Md, MD
Nephrology — Payments: $756.36
Nephrology $756.36
Jennifer Rivers, Aprn, APRN
Nephrology — Payments: $743.50
Nephrology $743.50